REVB Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Revelation Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$25.26 |
| 52 Week Low | US$0.70 |
| Beta | 0.18 |
| 11 Month Change | 3.18% |
| 3 Month Change | -25.61% |
| 1 Year Change | -95.29% |
| 33 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University
Oct 06Revelation Biosciences GAAP EPS of -$0.12
Aug 15Revelation Biosciences stock slides 47% on pricing $5M securities offering
Jul 26Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections
Mar 28Shareholder Returns
| REVB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.2% | -0.7% | -1.6% |
| 1Y | -95.3% | 19.8% | 30.8% |
Return vs Industry: REVB underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: REVB underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| REVB volatility | |
|---|---|
| REVB Average Weekly Movement | 33.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: REVB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: REVB's weekly volatility has increased from 24% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 9 | James Rolke | www.revbiosciences.com |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
Revelation Biosciences, Inc. Fundamentals Summary
| REVB fundamental statistics | |
|---|---|
| Market cap | US$1.35m |
| Earnings (TTM) | -US$15.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs REVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REVB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.90m |
| Earnings | -US$15.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did REVB perform over the long term?
See historical performance and comparison